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Abstract
Background: Recent evidence suggest that the innate immune system is implicated in the early
events of celiac disease (CD) pathogenesis. In this work for the first time we have assessed the
relevance of different proinflammatory mediators typically related to innate immunity in CD
predisposition.
Methods: We performed a familial study in which 105 celiac families characterized by the presence
of an affected child with CD were genotyped for functional polymorphisms located at regulatory
regions of IL-1α, IL-1β, IL-1RN, IL-18, RANTES and MCP-1 genes. Familial data was analysed with a
transmission disequilibrium test (TDT) that revealed no statistically significant differences in the
transmission pattern of the different genetic markers considered.
Results: The TDT analysis for IL-1α, IL-1β, IL-1RN, IL-18, and MCP-1 genes genetic variants did not
reveal biased transmission to the affected offspring. Only a borderline association of RANTES
promoter genetic variants with CD predisposition was observed.
Conclusion: Our results suggest that the analysed polymorphisms of IL-1α, IL-1β, IL-1RN, IL-18,
RANTES and MCP-1 genes do not seem to play a major role in CD genetic predisposition in our
population.
Background
Celiac disease (CD) is an autoimmune disorder of the
small intestine in which dietary gluten ingestion leads to
a chronic inflammatory status of the mucosa [1]. There is
strong evidence for a genetic component for CD, with the
HLA genes being the strongest genetic locus associated
with CD predisposition known to date. About 95% of CD
patients are carriers of the DQ2 molecule, encoded by
DQA1*05/DQB1*02 alleles, compared to ~10% of
healthy control subjects. Furthermore, the DQ8 molecule
(DQA1*0301/DQB1*0302 is also found more frequently
in CD patients although to a lesser extent [2]. Finally, a
role for genes located outside the HLA region has been
suggested since the overall contribution of HLA genes to
CD genetic predisposition is no more than 40% [1].
T CD4+ lymphocytes are key elements in the induction
and progression of CD pathogenesis. Certain gluten pep-
tides bound to DQ2 or DQ8 molecules cause prolifera-
tion and production of proinflammatory cytokines by
lamina propria CD4 +T cells [3]. Besides this activation of
adaptive immune response, recent evidences suggest that
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there is an implication of the innate immunity in the ini-
tial phases of CD [4]. In this regard, some gluten peptides
have been demonstrated to drive a danger signal that
leads to an activation of the innate immune system [5,6]
and additionally it is thought that bacteria may play a role
in CD [7]. In fact, CD patients show an up-regulation in
the expression of pro-inflammatory cytokines typically
related to the innate immune response, such us IL1, IL-18
and chemokines [6,8-10].
The IL1 gene cluster located in the chromosomal region
2q12-22 codifies for three proteins: IL-1α, IL-1β and IL-1
receptor agonist (IL-1RN), of which the two first are
strong inducers of inflammation while IL-1RN is an effec-
tive antagonist binding to the IL-1 receptor without acti-
vating the target cell [11]. These genes are polymorphic
bearing well-characterized single nucleotide polymor-
phisms (SNPs). Polymorphisms in IL-1α at position -889
C/T (rs1800587) and IL-1β at position -511 C/T
(rs1143627) were described [12,13]. Furthermore, recent
findings showed that the -511 C/T IL-1β genetic variant is
related to differences in IL-1β protein secretion [14]. The
IL-1RN gene contains within its second intron a variable
number of an 86-bp tandem repeats (rs380092) [15],
showing the allele 2 (IL-1RN*2; two repeats) an increased
frequency in a variety of autoimmune and inflammatory
disorders [16].
Another important member of the proinflammatory IL-1
family is IL-18, which is thought to be a key regulator of
cytokine expression [17]. Furthermore, a role for IL-18 in
the induction of an anti-gluten inflammatory response
has been suggested [10,18,19]. It is thought that IL-18
gene variation in the promoter region regulates the expres-
sion of this cytokine [20]. Interestingly, in the IL-18 pro-
moter region two SNPs -607 A/C (rs1946518) and -137
G/C (rs187238) were described, which are supposed to
alter the IL-18 promoter activity [21].
Moreover, raised levels of chemokines such us RANTES
(regulated upon activation, normal T-cells expressed and
secreted) and monocyte chemoatractant protein-1 (MCP-
1) have been observed in the primary immune response
to gluten in CD patients [6,8]. Interestingly, genetic vari-
ants within regulatory regions that can affect trancription
and protein production levels, RANTES  -403 G/A
(rs2107538) and -28 G/C (rs2280788) and MCP-1 -2518
G/A (rs1024611) SNPs, were described [22-24].
Taking into consideration these findings, in this work we
aimed to investigate the possible implication of IL-1α, IL-
1β, IL-1RN, IL-18, RANTES and MCP-1 functional poly-
morphisms in CD susceptibility.
Methods
Patients
In the present work we have analysed a panel of 105 celiac
families characterised by the presence of an affected child
with CD. The study participants were recruited at "Hospi-
tal Materno-Infantil" and "Hospital Clinico Universi-
tario", Granda, (Spain) and were of Spanish Caucasian
origin. All patients were diagnosed following the Euro-
pean Society of Paediatric Gastroenterology, Hepatology
and Nutrition (ESPGHAN) criteria for CD [25]. Their age
at study was 7.1 ± 3.9 years and the mean age for disease
diagnosis was 2.7 ± 2.72. A 60% were women and 40 %
men, showing an anthropometry at diagnosis (weight and
height) of P 3–100 percentile. The mean age of gluten
introduction was 6.4 ± 1.5 months. Typical symptoms
were observed in 72.2 % of patients and 27.8 % showed
atypical symptoms. All family members were genotyped
in DRB1 and DQB1. DQA1 typing was deduced from
DQB1 and DRB1 typing on the basis of the strong linkage
disequilibrium among HLA class II alleles.
Genotyping
DNA from patients and controls was obtained from
peripheral blood using standard methods. For all of the
considered SNPs, except IL-1RN and RANTES -403, sam-
ples were genotyped using a Taqman 5' allelic discrimina-
tion assay. Table 1 shows the Taqman MGB probes
sequences used for each polymorphism provided by the
Custom-Taqman-SNP-Genotyping-Assay (Applied Bio-
systems, Foster City, CA, USA). PCR reaction was carried
in a total reaction volume of 5 µl with the following
amplification protocol: denaturation at 92°C for 10 min,
followed by 50 cycles of denaturation at 92°C for 15 sec
and annealing and extension at 58°C for 1 min. Post-PCR,
the genotype of each sample was attributed automatically
by measuring the allelic specific fluorescence on the ABI
PRIM 7900 Sequence Detection Systems using the SDS
2.2.1 software for allelic discrimination (Applied Biosys-
tems, Foster City, CA, USA). RANTES -403 genotyping was
performed using a TaqMan SNP-Genotyping-Assay (part
number: C__15874407_10, Applied Biosystems, Foster
City, CA, USA).
The IL-1RN polymorphism was genotyped by PCR as pre-
viously described [26]. Briefly, we used a froward primer
5'- CTC AGC AAC ACCT CCT AT and reverse primer 5'-
TCC TGG TCT GCA GGT AA, two amplify five possible
alleles with different PCR fragment size: 410 bp (allele 1:
4 repeats), 240 bp (allele 2: two repeats), 325 bp (allele 3:
3 repeats), 500 bp (allele 4: 5 repeats), and 595 bp (allele
5: 6 repeats).
Statistical analysis
We used the UNPHASED software created for TDT and
case-control analysis [27]. We performed a TransmissionBMC Medical Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2350/6/29
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Disequilibrium Test (TDT), which assesses allele trans-
mission rates in simplex families and tests for deviation
from expected 50% transmission. For the haplotype anal-
ysis, pair-wise linkage disequilibrium measures were
investigated and haplotypes constructed using the expec-
tation-maximization (EM) algorithm implemented in
UNPHASED software. The power of the study to detect an
effect of a polymorphism in disease susceptibility was esti-
mated using the Quanto v 0.5 software (Department of
Table 1: Taqman probes used for cytokine genotyping
Polymorphism Taqman probe sequence
IL-1A -889 C/T (rs1800587) VIC – CCTTCAATGGTGTTGCC
FAM – CCTTCAATGATGTTGCC
IL-1B -551 C/T (rs1143627) VIC – CTGTTTTTATGGCTTTCA
FAM – CTGTTTTTATAGCTTTCA
IL-18 -607 C/A (rs1946518) VIC – ATCATTAGAATTTTATGTAATAAT
FAM – ATCATTAGAATTTTATTTAATAAT
IL-18 -137 G/C (rs187238) VIC – ACTATTTTCATGAAATCTTTTCT
FAM – TTTTCATGAAATGTTTTCT
RANTES -28 G/C (rs2280788) VIC – CCCCTCAACTGGC
FAM – CCCCTGAACTGGC
MCP-1 -2518 G/A (rs1024611) VIC – CAGACAGCTGTCACTTT
FAM – CAGACAGCTATCACTTT
Table 2: Allelic frequencies and percentage of transmission of IL-1α, IL-1β, IL-1RN, IL-18, RANTES and MCP-1 genetic variants in CD 
families.
Alelle frequency in 
parents (%)
T:NT % T P
IL-1A -551
C 70.4 111:125 47 0.08
T 29.6 52:38 58 0.08
IL-1B -889
T 67.6 110:111 49.7 NS
C 32.4 47:46 50.5 NS
IL-1RNVNTR
1 71.6 107:107 50 NS
2 26.8 43:42 50.6 NS
3 1.6 2:2 50 NS
IL-18 -607
C 61.7 102:103 49.7 NS
A 38.3 59:58 50.4 NS
IL-18 -137
G 75.9 124:124 50 NS
C 24.1 47:47 50 NS
RANTES -28
C 84.1 155:148 51 0.04
G 15.9 3:10 23 0.04
RANTES -403
G 85.7 141:128 52 0.06
A 14.3 23:36 39 0.06
MCP-1
A 72.8 117:129 47 NS
G 27.2 48:36 57 NS
T = transmitted, NT = not transmitted %T = percentage transmittedBMC Medical Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2350/6/29
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The transmission pattern for IL-1α -889, IL-1β -511 and
IL-1RN VNTR polymorphisms is shown in table 2. When
transmission of these genetic variants was analysed, none
of the alleles showed statistically significant skewing. IL-
1α -889 T allele was slightly more transmitted to the
affected children (58% transmission for allele T vs 47%
for allele C), however the p value failed to reach statisti-
cally significant level (Table 2). With regard to IL-1RN we
observed that alleles IL-1RN*1 and IL-1RN*2 were the
most frequent in our population (71.6% and 26.8%
respectively), accordingly with previously studies in
Caucasian populations [26].
IL18 gene
The TDT analysis for -607 A/C and -137 G/C IL-18 pro-
moter genetic variants did not reveal biased transmission
of any of the alleles to the affected offspring (Table 2).
The haplotype estimation for the -607 A/C and -137 IL-18
promoter variants revealed complete linkage disequilib-
rium between the two variants (D' = 1). We observed three
out of the four possible haplotypic combinations in CD
families (Table 3). The transmission pattern of IL-18 pro-
moter haplotypes did not show any statistically significant
skewing (Table 3).
MCP-1 and RANTES
After analyzing the MCP-1 -2518 G/A alleles transmission
we observed that none of the alleles was preferentially
transmitted from heterozygous parents to the affected off-
spring (Table 2). Regarding to the RANTES  promoter
genetic variants the mutant alleles -403 A and -28 G
showed an overall allele frequency similar to that
expected for Caucasian populations (84.1% and 96.5%
respectively in our population) [29,30]. The transmission
of both -403G/A and -28 C/G SNPs showed a slightly
deviation from the 50% expected transmission pattern
(Table 2). Alleles -403 G and -28 C were more transmitted
to the affected offspring with borderline significance (P =
0.04 and P = 0.06 respectively) (Table 2). In addition, we
estimated haplotypes for both genetic variants. Three out
of the four haplotypic combinations were observed, being
the -403G/-28C and -403A/-28C haplotypes the most
common in CD families. No significant distorted trans-
mission pattern for RANTES  promoter haplotypes was
observed (Table 3).
Discussion
CD is considered a model for autoimmune disorders since
many of the components that generate the altered
immune response to gluten have been well characterized
[1]. However, there are some relevant events of CD patho-
genesis that remain unclear, for instance the stimuli that
drives the high IFNγ levels in the small intestine of CD
patients and why only one out of 20–30 DQ2-positive
individuals develops CD [3]. An explanation for these
questions might be provided from recent studies that
point out a role for the innate immunity in CD [4]. This
finding supports a novel focus of research in CD molecu-
lar and genetic basis, opening a new field for the func-
tional search of CD candidate genes.
In this work, for the first time we have assessed the rele-
vance of IL-1α, IL-1β, IL-1RN, IL-18, RANTES and MCP-1
genes in CD predisposition. All these genes have been pre-
viously associated with susceptibility to several
autoimmune disorders [31-40]. However, we failed to
detect an association of IL-1α, IL-1β, IL-1RN, IL-18, and
MCP-1 genes with CD predisposition using a TDT analysis
in our cohort of 105 simplex CD families. Only a border-
line significant association of RANTES promoter genetic
variants with CD predisposition was observed.
Several studies have focused on the role of RANTES  -
403G/A and -28 G/C promoter polymorphisms in suscep-
tibility to different autoimmune disorders. The RANTES -
403A allele has been associated with susceptibility to mul-
tiple sclerosis (MS) and polymialgia rheumatica [41,42].
On the other hand, the RANTES -28G allele was observed
Table 3: Transmission pattern of haplotypes inferred for IL-18 and RANTES promoter genetic variant in CD families
Gene Haplotype Transmitted (%) No transmitted (%) P
Il-18 -607A/-137G 37 (24) 35 (22.5) NS
-607A/-137C 19 (12.2) 20 (13) NS
-607C/-137G 99 (63.8) 100 (64.5) NS
RANTES -403G/-28A 3 (1.4) 8 (5.2) NS
-403A/-28C 19 (12.3) 26 (16.8) NS
-403G/-28C 132 (85.7) 119 (81.5) 0.05BMC Medical Genetics 2005, 6:29 http://www.biomedcentral.com/1471-2350/6/29
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to be a genetic risk for clinical complications such us dia-
betic neprhopathy, early onset of MS, lower levels of C3 in
SLE, and higher incidence of central nervous system lupus
[37,38,41]. Both RANTES -403A and -28G alleles were
associated with higher RANTES expression levels [22,23].
However, considering the multiple testing of the 6 differ-
ent genes of our study, the association observed for
RANTES promoter variants in our population can not be
considered as being significant. Therefore, our results of
RANTES suggest that further studies should be performed
to clarify the role of RANTES in CD and autoimmune dis-
eases in general.
Using a familial approach we eliminate the risk of popu-
lation stratification derived from case-control association
studies. In addition, we estimated that our study design
would have considerable power to detect the effect of a
polymorphism with moderate to high risk for CD. Assum-
ing an additive model, a minor allele frequency of 0.30
(corresponding to a median value of the majority of mark-
ers considered) and RR of 1.8 we would reach 81% power
to detect an association in our population. Nevertheless,
under a dominant model the power drops to 49% and
considering a lower disease allele frequency, for instance
0.16 as is the case of RANTES -28, our study power would
decrease to a 64% for a RR of 1.8, and increases to 82%
when we assume a RR of 2.0. For this reason, the low level
of significance that our TDT analysis reached for RANTES
promoter genetic variants might well reflect a true posi-
tive, and therefore needs further confirmation using a
larger group of CD families.
Taking into account our findings, it is suggested that the
analysed genetic polymorphisms of IL-1α, IL1-β, IL-1RN,
IL-18, RANTES and MCP-1 genes seem not to play a major
role in CD susceptibility in our population. It might be
possible that the release of these cytokines and chemok-
ines observed in CD patients could be derived from the
activity of other innate immunity related pro-inflamma-
tory mediators with higher influence in disease pathogen-
esis. In this regard, it is known that in CD the cytokine
expression pattern in response to gluten is strongly domi-
nated by IFNγ [43]. Of note, in a recent work we assessed
the influence of a functional dinucleotide polymorphism
of IFNγ gene in CD predisposition. An association of a
higher IFNγ producer allele with CD was observed, sup-
porting a possible explanation for the high levels of INFγ
observed in intestinal mucosa of CD patients [44].
Other proinflammatory mediators related with innate
immunity such as, TNF-α and IL-12, has been analysed
with respect to CD susceptibility. In accordance with our
findings no evidence of association was found between IL-
12 and CD in two independent studies [45,46]. Regarding
TNF-α it has been difficult to dissect the relevance of this
genetic marker in CD since it maps within HLA clas III
region and it shows linkage disequilibrium with CD dis-
ease predisposing DQ2 alleles. In fact controversial results
have been obtained, and there is no consensus about an
independent or due to linkage disequilibrium role of
TNF-α in CD susceptibility [47,48].
Conclusion
Our results suggest that IL-1α, IL1-β, IL-1RN, IL-18,
RANTES and MCP-1 genetic variants do not play a major
role in CD genetic predisposition, although the suggestive
evidence for RANTES deserves further investigation. Fur-
thermore, we consider the innate response an intriguing
focus of research and it should be of interest to investigate
the role of other cytokines up-regulated in the early events
of CD.
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